The Kanabo share price: should I get involved or steer clear?

After a strong first week since the IPO, the Kanabo share price is up around 400%. Jonathan Smith finds out more about this wellness cannabis stock.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3D Word IPO with Target on Chalkboard Background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Kanabo Group (LSE:KNB) share price has performed exceptionally well in the first week of trading following the IPO last week. From an issue price of 6.5p, the shares closed last Friday at 31p. This reflects a gain of almost 400%. The first few weeks of a new stock trading on the LSE are usually volatile. Yet even by IPO standard, this was a big move. So what’s the story here, and should I look to buy?

The backstory on Kanabo

Kanabo manufactures CBD products, marijuana pods and inhalers, and other similar items. It says that all the cannabis and other drug-related products are purely for medicinal purposes and wellness. Although Kanabo shares are unlikely to be included in any ESG investors portfolio, it’s technically legal. Cannabis (for medical use) was legalised in the UK back in 2018. Regulators have also given the green light for these types of companies to list on the LSE.

It thus became the first medical cannabis company to go public here in the UK. Given the Kanabo share price performance in the first week, I’d say it’s been a success so far. The company finds itself with a market capitalisation of around £112m. The funds raised from the IPO are going to be ploughed back into product development.

Could the Kanabo share price head higher?

Firstly, let’s look at the size of the market. There’s no question that the cannabis market is growing globally. More countries are legalising it, leading to forecasts that in Europe and the UK, the market could be worth £1.7bn over the next four years. Clearly, Kanabo is in a good position to reap the benefits of this growth. On the other hand, the market is still relatively new here in Britain. There’s no blueprint for Kanabo to follow.

As a company that’s just listed, it’s hard for me to find all the financial details to give me more insight. A private limited company doesn’t have to share as much financial info as a public one does. From what I can find, the business is loss-making. The latest loss after tax for the 2019 period was £360k. Without more detailed financial reporting, I can’t glean much aside from that. And investing in a company that has been losing money doesn’t seem a smart play.

Given the size of Kanabo, I think the share price could head higher as it could become a takeover target. A larger pharmaceutical company that sees the growth potential in this sector could look to buy it. Depending on the premium put on the Kanabo share price at that time, shareholders could see a large profit from buying now. But that’s not guaranteed, of course.

As I’ve flagged in recent IPO articles on Bumble and Moonpig, I’m not a fan of investing just after an IPO. This is the same risk with Kanabo. I’d much prefer to sit on the sidelines for a month and see where the share price settles before making a move. This reduces my chances of large losses during the volatile initial trading period.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

jonathansmith1 has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Surprise! This monopoly stock has taken over my Stocks and Shares ISA (again)

Our writer has a (nice) dilemma in his Stocks and Shares ISA portfolio after one incredible growth stock rocketed higher…

Read more »

Investing Articles

10.5% yield – but could the abrdn share price get even cheaper?

Christopher Ruane sees some things to like about the current abrdn share price. But will that be enough to overcome…

Read more »

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »

Investing Articles

Is December a good time for me to buy UK shares?

This writer is weighing up which shares to buy for his portfolio next month, and one household name from the…

Read more »

Investing Articles

Is it time to dump my Lloyds shares and never look back?

Harvey Jones was chuffed with his Lloyds shares but recent events have made him rethink his entire decision to go…

Read more »